Haifan Xu
- Topics
- Cancer-related molecular mechanisms research (4 papers)Cancer Research and Treatments (2 papers)MicroRNA in disease regulation (2 papers)
- Journals
- Scientific ReportsBiochemical and Biophysical Research CommunicationsInternational Journal of Cancer
- Partner nations
- ChinaUnited States
In The Last Decade
Haifan Xu
13 papers receiving 412 citations
Peers
Comparison fields: 5 of 72
- Molecular Biology 280
- Cancer Research 261
- Immunology 66
- Oncology 52
- Pulmonary and Respiratory Medicine 30
Countries citing papers authored by Haifan Xu
This map shows the geographic impact of Haifan Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haifan Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haifan Xu more than expected).
Fields of papers citing papers by Haifan Xu
This network shows the impact of papers produced by Haifan Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haifan Xu. The network helps show where Haifan Xu may publish in the future.
Co-authorship network of co-authors of Haifan Xu
This figure shows the co-authorship network connecting the top 25 collaborators of Haifan Xu. A scholar is included among the top collaborators of Haifan Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haifan Xu. Haifan Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 2 | |
| 3 | 0 | |
| 4 | 0 | |
| 5 | 3 | |
| 6 | Ambrosin sesquiterpene lactone exerts selective and potent anticancer effects in drug-resistant human breast cancer cells (MDA-MB-231) through mitochondrial mediated apoptosis, ROS generation and targeting Akt/β-Catenin signaling pathway. | 5 |
| 7 | Inhibition of cancer cell growth by Tangeretin flavone in drug-resistant MDA-MB-231 human breast carcinoma cells is facilitated via targeting cell apoptosis, cell cycle phase distribution, cell invasion and activation of numerous Caspases. | 10 |
| 8 | 9 | |
| 9 | 24 | |
| 10 | 30 | |
| 11 | 44 | |
| 12 | 43 | |
| 13 | 16 | |
| 14 | 24 | |
| 15 | 201 |
About Haifan Xu
Haifan Xu is a scholar working on Cancer Research, Toxicology and Behavioral Neuroscience, having authored 15 papers that have together received 414 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (4 papers), Cancer Research and Treatments (2 papers) and MicroRNA in disease regulation (2 papers). The work is most often cited by research in Cancer Research (261 citations), Molecular Biology (280 citations) and Immunology (66 citations). Haifan Xu has collaborated with scholars based in China and United States. Frequent co-authors include Jing Zhong, Ruirui Yang, Xi Zeng, Ying Zeng, Yinghui Xu, Zhuo Chen, Huimin Wu, Yong Xiao, Zhouyu Ning and Jing Xie. Their work appears in journals such as Scientific Reports, Biochemical and Biophysical Research Communications and International Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.